Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTONG 2508-ADAPT-Lung adaptive adjuvant sintilimab for non-pCR NSCLC
ChiCTR2600117155Phase 2Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Third People's Hospital of Chengdu. Primary endpoint: 2-year event-free survival rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117155.